239 related articles for article (PubMed ID: 35857626)
1. Genomic and epigenomic
Menghi F; Banda K; Kumar P; Straub R; Dobrolecki L; Rodriguez IV; Yost SE; Chandok H; Radke MR; Somlo G; Yuan Y; Lewis MT; Swisher EM; Liu ET
Sci Transl Med; 2022 Jul; 14(652):eabn1926. PubMed ID: 35857626
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Ter Brugge P; Moser SC; Bièche I; Kristel P; Ibadioune S; Eeckhoutte A; de Bruijn R; van der Burg E; Lutz C; Annunziato S; de Ruiter J; Masliah Planchon J; Vacher S; Courtois L; El-Botty R; Dahmani A; Montaudon E; Morisset L; Sourd L; Huguet L; Derrien H; Nemati F; Chateau-Joubert S; Larcher T; Salomon A; Decaudin D; Reyal F; Coussy F; Popova T; Wesseling J; Stern MH; Jonkers J; Marangoni E
Nat Commun; 2023 Apr; 14(1):1958. PubMed ID: 37029129
[TBL] [Abstract][Full Text] [Related]
3. BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer.
Tazzite A; Jouhadi H; Benider A; Nadifi S
Curr Drug Targets; 2020; 21(10):962-973. PubMed ID: 32013831
[TBL] [Abstract][Full Text] [Related]
4. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
5. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lenz L; Neff C; Solimeno C; Cogan ES; Abramson VG; Boughey JC; Falkson C; Goetz MP; Ford JM; Gradishar WJ; Jankowitz RC; Kaklamani VG; Marcom PK; Richardson AL; Storniolo AM; Tung NM; Vinayak S; Hodgson DR; Lai Z; Dearden S; Hennessy BT; Mayer EL; Mills GB; Slavin TP; Gutin A; Connolly RM; Telli ML; Stearns V; Lanchbury JS; Timms KM
Breast Cancer Res Treat; 2023 Nov; 202(1):191-201. PubMed ID: 37589839
[TBL] [Abstract][Full Text] [Related]
6. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
7. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt A; Tovey H; Cheang MCU; Kernaghan S; Kilburn L; Gazinska P; Owen J; Abraham J; Barrett S; Barrett-Lee P; Brown R; Chan S; Dowsett M; Flanagan JM; Fox L; Grigoriadis A; Gutin A; Harper-Wynne C; Hatton MQ; Hoadley KA; Parikh J; Parker P; Perou CM; Roylance R; Shah V; Shaw A; Smith IE; Timms KM; Wardley AM; Wilson G; Gillett C; Lanchbury JS; Ashworth A; Rahman N; Harries M; Ellis P; Pinder SE; Bliss JM
Nat Med; 2018 May; 24(5):628-637. PubMed ID: 29713086
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Manzo J; Puhalla S; Pahuja S; Ding F; Lin Y; Appleman L; Tawbi H; Stoller R; Lee JJ; Diergaarde B; Kiesel BF; Yu J; Tan AR; Belani CP; Chew H; Garcia AA; Morgan RJ; Wahner Hendrickson AE; Visscher DW; Hurley RM; Kaufmann SH; Swisher EM; Oesterreich S; Katz T; Ji J; Zhang Y; Parchment RE; Chen A; Duan W; Giranda V; Shepherd SP; Ivy SP; Chu E; Beumer JH;
Cancer Chemother Pharmacol; 2022 May; 89(5):721-735. PubMed ID: 35435472
[TBL] [Abstract][Full Text] [Related]
11. BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction.
Zikan M; Vecerova L; Dubova O; Sehnal B; Soukupova J
J Cancer Res Ther; 2023; 19(3):684-687. PubMed ID: 37470594
[TBL] [Abstract][Full Text] [Related]
12. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
13. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
14. Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer.
Blanc-Durand F; Tang R; Pommier M; Nashvi M; Cotteret S; Genestie C; Le Formal A; Pautier P; Michels J; Kfoury M; Hervé R; Mengue S; Wafo E; Elies A; Miailhe G; Uzan J; Rouleau E; Leary A
Clin Cancer Res; 2023 Aug; 29(16):3124-3129. PubMed ID: 37067532
[TBL] [Abstract][Full Text] [Related]
15. Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.
Kraya AA; Maxwell KN; Wubbenhorst B; Wenz BM; Pluta J; Rech AJ; Dorfman LM; Lunceford N; Barrett A; Mitra N; Morrissette JJD; Feldman M; Nayak A; Domchek SM; Vonderheide RH; Nathanson KL
Clin Cancer Res; 2019 Jul; 25(14):4363-4374. PubMed ID: 30914433
[TBL] [Abstract][Full Text] [Related]
16. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
Garg K; Levine DA; Olvera N; Dao F; Bisogna M; Secord AA; Berchuck A; Cerami E; Schultz N; Soslow RA
Am J Surg Pathol; 2013 Jan; 37(1):138-46. PubMed ID: 23232854
[TBL] [Abstract][Full Text] [Related]
18. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
[TBL] [Abstract][Full Text] [Related]
19. Mosaic
Schwartz M; Ibadioune S; Chansavang A; Vacher S; Caputo SM; Delhomelle H; Wong J; Abidallah K; Moncoutier V; Becette V; Popova T; Suybeng V; De Pauw A; Stern MH; Colas C; Mouret-Fourme E; Stoppa-Lyonnet D; Golmard L; Bieche I; Masliah-Planchon J
J Med Genet; 2024 Feb; 61(3):284-288. PubMed ID: 37748860
[TBL] [Abstract][Full Text] [Related]
20. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
von Wahlde MK; Timms KM; Chagpar A; Wali VB; Jiang T; Bossuyt V; Saglam O; Reid J; Gutin A; Neff C; Lanchbury JS; Hatzis C; Hofstatter E; Pusztai L
Clin Cancer Res; 2017 Mar; 23(5):1193-1199. PubMed ID: 27601588
[No Abstract] [Full Text] [Related]
[Next] [New Search]
